Adenosine to facilitate the clipping of cerebral aneurysms: literature review

Virendra R Desai,1 Alejandro L Rosas,2 Gavin W Britz1

To cite: Desai VR, Rosas AL, Britz GW. Adenosine to facilitate the clipping of cerebral aneurysms: literature review. Stroke and Vascular Neurology 2017;0:e000082. doi:10.1136/svn-2017-000082

ABSTRACT
Cerebral aneurysms have a high mortality rate when ruptured. Endovascular techniques have improved substantially in treating this pathology. However, surgical clip ligation remains the preferred option for some aneurysms. Various techniques are used intraoperatively to assist the surgeon in dissecting the aneurysm dome free of surrounding tissue and placing a clip around the neck safely and effectively so that no nearby perforating vessels are affected and no residual remains. These techniques include temporary clip ligation, endovascular balloon occlusion and cardiac standstill. Adenosine use is one viable option for induced cardiac arrest leading to a short period of controlled hypotension. Its predictable course of action, rapid onset and offset and rare incidence of adverse side effects make it an attractive agent in this regard. Below, we provide an introduction to adenosine use, describing its pharmacokinetic properties, indications, contraindications, complications and future directions.

INTRODUCTION
Aneurysmal subarachnoid haemorrhage has a high mortality rate (40%–50%), and thus, prompt recognition of and proper management of aneurysms, both ruptured and unruptured, is warranted.4 With advancements in endovascular technique, the majority of intracerebral aneurysms are treated in this manner. However, some aneurysms, based on their location and/or morphology, still require surgical clip ligation. However, some aneurysms, based on their location and/or morphology, still require surgical clip ligation.

Several techniques are available to assist the surgeon in dissecting the aneurysm free of surrounding tissue, improving visualisation of the aneurysm’s neck and placing a permanent clip to completely obliterate it while maintaining patency of surrounding perforating vessels.2 Such techniques include temporary clip ligation of the proximal blood vessel, temporary cross-clamping of the extracranial carotid artery in the neck, endovascular balloon occlusion with suction, extracranial-to-intracranial bypass and cardiac standstill.2–4 Cardiac standstill allows controlled hypotension, which can be used to reduce aneurysmal wall tension, decrease the risk of rupture and facilitate successful clip ligation and is also used to decrease bleeding.5 Current methods for cardiac standstill include non-pharmacological methods such as deep hypothermic circulatory arrest on cardiopulmonary bypass and rapid ventricular pacing, as well as pharmacological methods, with the administration of sodium nitroprusside (NP), nitroglycerin or adenosine.6–7

However, many of these methods have numerous drawbacks. Endovascular techniques can cause dissection or distal arterial embolic occlusion.3–4 Cardiopulmonary bypass has risks of arterial injury at the site of cannulation, embolic occlusion related to an aortic plaque or postoperative intracranial haemorrhage, since it requires anticoagulation.3–4 Temporary clip ligation of a proximal vessel has risks of stroke, dissection or rupture and also decreases visualisation.2 3 8 In instances where temporary arterial occlusion is difficult for anatomical reasons or impractical, adenosine use can be beneficial.4 Sodium NP and nitroglycerin have a number of side effects, including cyanide toxicity, tachyphylaxis, rebound hypertension, increased intracranial pressure and methemoglobinemia.3–9 In addition, nitroglycerin has a slow onset and unpredictable action.5 Ideal criteria for flow arrest in vascular surgery include the following:

- Predictable effects (especially degree and duration of hypotension)
- Few pharmacological side effects
- Titratability
- Technical feasibility and simplicity
- Low risk for procedure-related complications

In this review article, we provide background on adenosine use in intracranial aneurysm surgery.

ADENOSINE PHARMACOKINETICS
Adenosine is a nucleoside analogue that binds to cardiac A1 receptors, which are membrane G-protein-coupled receptors. This initiates a cascade through activation of adenyl cyclase, decreasing intracellular cyclic AMP,
which results in decreased inward calcium conductance.\textsuperscript{11,12} This leads to multiple cardiac effects, including depressed sinoatrial (SA) node activity (negative chronotropic effect), slowed atrioventricular (AV) nodal conduction (negative dromotropic effect) and decreased atrial contractility and ventricular automaticity.\textsuperscript{12,13}

The clinical effect is seen 10–20 s after bolus injection of adenosine, leading to AV nodal blockade, bradycardia, sinus pauses and cardiac arrest, all of which manifest as a profound decrease in cardiac output and mean arterial pressure (MAP).\textsuperscript{4,11} Adenosine is rapidly cleared from blood by uptake into erythrocytes and vascular endothelial cells, having a short half-life of 0.6–20 s.\textsuperscript{4,10,11} Owall et al used adenosine by continuous infusion to a mean of 29 min of controlled hypotension, with mean arterial blood pressure restored to preadenosine levels 0.5–3 min after discontinuation, except in two cases with cardiac arrhythmia.\textsuperscript{14} Because of its rapid onset and offset, a bolus of adenosine can allow a transient asystole with temporary hypotension that decompresses the aneurysm sac and improves visualisation without the negative effects of prolonged hypotension.\textsuperscript{2}

Adenosine also acts on coronary vasculature via opening of potassium channels. This leads to hyperpolarisation of vascular smooth muscle cells, causing arterial vasodilatation. This can produce a coronary steal phenomenon so that underperfused areas, where coronary arteries are already maximally dilated, may become ischaemic. This principle underlies its use in cardiac stress testing, and it also underscores the importance of close cardiac monitoring when used in aneurysm surgery.\textsuperscript{12,13}

Lastly, adenosine acts on \(A_2\)-adenosine receptors on bronchial smooth muscle to cause contraction. Thus, it may induce bronchospasm, although this has only occurred in several case reports in patients with asthma or chronic obstructive pulmonary disease (COPD).\textsuperscript{15}

**PAST USE IN CEREBROVASCULAR SURGERY**

In 1984, Sollevi et al studied 10 patients undergoing aneurysm surgery. An adenosine infusion of 0.14 mg/kg/min lead to a decrease in MAP by 43\% (82 to 46 mm Hg) and a mean hypotensive period of 32 min, without signs of tachyphylaxis. They pretreated with dipyridamole (adenosine uptake inhibitor) to reduce the dose of adenosine required (50% more adenosine required without pretreatment).\textsuperscript{5,14} Pulmonary vascular resistance, central venous pressure, arterial lactate and partial pressure of oxygen in arterial blood were unchanged. Whole body oxygen consumption decreased by 13%.\textsuperscript{5}

In 1987, Owall et al studied 47 patients (46 undergoing aneurysmal clip ligation and 1 arteriovenous malformation (AVM) resection). Adenosine was infused, starting at 0.04 mg/kg/min and increasing by 0.04 every 30 s until a desired MAP of 40–50 mm Hg was reached (range: 0.088–0.530 mg/kg/min). The hypotensive period lasted 29 min on average. There were no changes in pulmonary arterial pressure, pulmonary capillary wedge pressure, pH, base excess or partial pressure of carbon dioxide in arterial blood, and no reflex tachycardia or rebound hypotension was seen.\textsuperscript{14}

While Sollevi et al and Owall et al used adenosine infusions,\textsuperscript{4,14} more recently adenosine boluses have been implemented for cardiac arrest. In 1999, Groff et al reported the first use of adenosine bolus to clip an unruptured basilar tip aneurysm in one patient. In this study, the authors used concomitant infusion of sodium NP and gave three doses of adenosine: 6 mg, then 12 mg and then another 12 mg, which caused 8–13% of profound hypotension (MAP \(\sim\) 15 mm Hg) and allowed the safe and successful placement of a clip.\textsuperscript{8} In 2010, Powers et al used adenosine by bolus for clipping anterior circulation aneurysms in six patients, administering escalating doses until 30 s of asystole was achieved (6 mg, 12 mg, 18 mg, 24 mg and 36 mg). They found a rate of 1 mg adenosine resulting in 1 s of asystole on average.\textsuperscript{11}

However, there are no specific guidelines on bolus dosing. Two main studies address this question.\textsuperscript{4,10} Hashimoto et al used adenosine dosing in endovascular glue embolisation of AVMs with five patients (four adults and one child). The initial adenosine dose was 0.25–0.35 mg/kg, with escalation by 10–20 mg per injection, till 20–30 s of MAP at 25–30 mm Hg was achieved, with 3–10 min between each injection. The authors also gave sodium NP, lowering MAP by 10\% from baseline, to reduce postadenosine rebound hypertension. They created a scatter plot with weight-based dosing on the x-axis (mg/kg) and several variables on the y-axis: duration of asystole, duration of MAP \(<\) 50, duration of MAP \(<\) 30 and MAP for first 20 s. All of these variables had a linear relation. In other words, both the duration of asystole and a MAP \(<\) 30–50 is linearly correlated with adenosine dose.\textsuperscript{10,16} Their model shows 0.88 mg/kg is needed for 45 s of moderate hypotension (MAP \(<\) 50) and 2.15 mg/kg for profound hypotension (MAP \(<\) 30).\textsuperscript{10}

Hoping to demonstrate the dose–response curve for adenosine during cerebral aneurysm clipping, Bebawy et al retrospectively reviewed 24 patients who had adenosine administration during aneurysmal clip ligation, with two-thirds unruptured and one-third ruptured and two-thirds located in the anterior circulation and one-third posterior.\textsuperscript{4} Based on their results, the authors recommend dosing at 0.3–0.4 mg/kg of ideal body weight (IBW) for 45 s of profound controlled hypotension, systolic blood pressure \(<\) 60, when used in combination with a low dose volatile anaesthetic, remifentanil infusion and propofol-induced burst suppression.\textsuperscript{3} They used IBW, instead of actual body weight, because the volume of distribution of adenosine (ie, the blood volume between the intravenous injection site and the right atrium and ventricle) is unlikely to change with obesity.\textsuperscript{4} Unlike the study by Hashimoto et al above, Bebawy et al needed 1/5 to 1/7 the dose of adenosine primarily because of remifentanil usage, which depresses SA node activation and AV node conduction, whereas the sodium NP Hashimoto et al used can increase electrical conduction through these nodes.\textsuperscript{4,10}
Bendok et al report a retrospective review of 40 patients undergoing aneurysmal clipping with adenosine use, both anterior and posterior circulations, 10 ruptured and 30 unruptured. These authors used bolus dosing of 0.3–0.4 mg/kg as in Bebawy et al with successful clip ligation in 35/40 patients (87.5%).

Guinn et al retrospectively studied 27 patients with primarily anterior circulation aneurysms. Based on their results, the authors recommend dosing 0.24–0.42 mg/kg to get 30–60 s of hypotension and bradycardia. They suggest that hypotension rather than asystole is the single most important factor in adenosine success.

Andrade-Barazarte et al retrospectively reviewed eight patients who received adenosine during aneurysm surgery in a contralateral approach to ophthalmic segment internal carotid artery aneurysms. All were unruptured, small and saccular. The median dose of adenosine was 22.5 mg (range 5–50 mg) for 20–40 s of asystole.

Significant interpatient variability exists in response to adenosine and duration of asystole, and thus, the ideal dose for a certain patient is unknown until multiple test doses are given. However, multiple test dosing with repeated cardiac arrest periods may cause cardiac or end-organ ischaemia and are impractical, or even impossible, when emergent or unexpected complications arise, such as intraoperative rupture.

Lee et al, however, compared a multiple, escalating dose regimen with a predetermined dose regimen, based on 0.3–0.4 mg/kg and found essentially equivalent safety profiles between the two, with no cardiac complications other than two self-limited, short-lasting atrial fibrillation events in the predetermined dose group.

Adenosine was used after intraoperative rupture to prevent devastating bleeding in 16 patients, allowing successful clip ligation with no adverse consequences in all cases. Powers et al also report a case in which intraoperative rupture occurred and adenosine was used to decrease bleeding, improve visualisation and eventually perform a bypass with external carotid artery to the second segment of the middle cerebral artery with saphenous vein graft.

Vealey et al administered six large doses in succession over a 12 min time period to achieve control of a left middle cerebral arterial aneurysm that had ruptured. Rapid ventricular pacing has a more predictable response time, and thus can be used in times of unanticipated complications, but is more invasive and complex from an anaesthesia standpoint.

**INDICATIONS/STRENGTHS**

As noted above, adenosine use can induce temporary asystole and hypotension to decompress the aneurysmal dome, except when the aneurysm is calcified or fibrotic, allowing the surgeon to dissect the aneurysmal plane. Currently, no specific indications for adenosine use exist, but several authors have provided expert opinion on appropriate instances for its usage (table 1).

While temporary clipping is a valuable tool, it cannot be applied in all cases. This is especially true for large or deep aneurysms in narrow corridors or near the skull base where temporary clip ligation can further obscure a limited view or is even entirely impossible. In these situations, adenosine-induced cardiac arrest relaxes the brain and may improve visualisation in narrow corridors. Moreover, temporary clip ligation only decreases blood flow from one direction, while adenosine-induced hypotension is more global and, in certain instances, can more effectively decompress the aneurysmal dome.

Intraoperative aneurysmal rupture significantly increases morbidity and mortality, likely secondary to the bleeding itself or the ineffective or dangerous tactics employed by the surgeon. In this scenario, while temporary clipping is considered the gold standard, adenosine can be used as an effective synergistic tool. In fact, Wright et al state that intraoperative rupture is the ‘clearest indication for adenosine’, especially when rupture occurs early in the dissection, before proximal and distal control have been achieved. Nussbaum et al report one case

**Table 1**

<table>
<thead>
<tr>
<th>Indications</th>
<th>Contraindications*</th>
<th>Absolute vs relative contraindication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Large and/or deep aneurysms in narrow corridors where temporary clip ligation is difficult or not possible</td>
<td>Severe reactive airway disease</td>
<td>Absolute</td>
</tr>
<tr>
<td>In synergy with temporary clipping, especially during intraoperative aneurysmal rupture</td>
<td>Severe coronary artery disease</td>
<td>Absolute</td>
</tr>
<tr>
<td>Instances in which temporary clipping fails</td>
<td>Pre-existing cardiac conduction abnormalities</td>
<td>Relative</td>
</tr>
<tr>
<td>To improve visualisation of adjacent perforating arteries</td>
<td>Allergy</td>
<td>Relative</td>
</tr>
<tr>
<td></td>
<td>Dipyridamole, methylxanthines and nimodipine inhibit Relative adenosine breakdown and uptake and can increase levels</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Calcified or fibrotic aneurysmal wall/dome</td>
<td>Relative</td>
</tr>
</tbody>
</table>

*Mostly provided as expert opinion by Khan et al.
where temporary clipping was insufficient after intraoperative aneurysmal rupture; however, after adenosine usage, a clip was applied successfully. In their case, an anterior communicating artery aneurysm was associated with a right parietal AVM. Intraoperative rupture caused bleeding that could not be controlled with temporary clipping of the first segment of the anterior cerebral artery (A1) segment of the anterior cerebral artery. Thus, 12 mg of adenosine was given, which caused 25 s of asystole, allowing visualisation and then successful clip ligation.24 Deb et al report two cases of adenosine use during intraoperative rupture.25 One patient received 18 mg (0.5 mg/kg) intravenously in conjunction with temporary clipping after aneurysmal rupture, resulting in 20 s of asystole and allowing successful clip ligation with no long-term consequences.25 The second patient received two 18 mg bolus doses of adenosine with 25 s of asystole initially and then 15 s, allowing successful clip ligation, although cardiac arrest requiring electrical resuscitation occurred and the patient suffered lower cranial nerve palsies, necessitating tracheostomy and prolonged hospitalisation.25 This patient however had a history of interstitial lung disease, increasing her risk of complication with adenosine use, as well as 1.5 L of blood loss after aneurysmal rupture and between the sequential adenosine doses.25 Adenosine can also be used in cases where temporary clip ligation fails.22 Heppner et al report a case of a basilar tip aneurysm that could not be clipped with temporary clipping of the proximal basilar artery. While temporary clipping allowed further dissection of the aneurysmal dome, the authors could not visualise all the perforators extending from the aneurysm, and thus, clipping at this point was determined unsafe. They proceeded to administer escalating doses of adenosine, up to multiple 36 mg doses, which allowed enough visualisation to dissect the posterior perforators free from the aneurysm and successfully clip the aneurysm.22

CONTRAINDICATIONS
Overall, adenosine via bolus or by infusion is safe to use because of very limited side effects that are rapidly reversible with termination of administration, and it can be easily titrated to a desired effect.2 26 Nevertheless, some contraindications exist (table 1).

Adenosine can cause myocardial ischaemia in patients with coronary artery disease; it vasodilates healthy coronary arteries but not diseased ones, because they are already maximally dilated. This can cause a coronary steal phenomenon shunting blood away from diseased, underperfused areas to non-ischaemic areas. This principle underlies adenosine usage in cardiac stress testing. Multiple authors caution its use in patients with a preoperative history of myocardial infarction (MI) and recommend avoiding it in patients with severe left main coronary artery stenosis (80%) or severe multivessel coronary artery disease (three vessels or grafts with 80% stenosis).3 4 12 14 15 23

Adenosine-induced AV block is due to a direct adenosine effect rather than a manifestation of ischaemia, and this fact underlies its clinical use in stopping supraventricular tachycardia.15 20 The Adenoscan Multicenter Trial Registry was a prospective phase III trial using fixed dose, continuous infusion adenosine in patients referred for clinically indicated cardiac perfusion imaging who were unable to perform exercise stress testing. A dosage of 0.14 mg/kg/min of adenosine was infused for 6 min but terminated early if the patient developed significant side effects. In 9256 patients, 12 had bronchospasm (0.13%), 1 had an MI (0.01%) and 1 developed pulmonary oedema (0.01%). Only 4.7% of the total adverse events were classified as severe by the investigators.12 15 20 While 7.6% of patients (706 out of 9256) developed transient atrioventricular conduction block, the authors note that there was no difference in occurrence of ischaemia between those with versus without AV block.

Adenosine-induced sustained AV blockade is a rare side effect. Makaryus et al report one patient who developed sustained AV block after adenosine cardiac stress testing with adenosine infusing at 0.14 mg/kg/min for 5 min and required postprocedure permanent pacemaker implantation.12 This patient had no evidence of AV node blockade on prestress test ECG, and thus the authors state that although this side effect is rare, it is possible, especially in patients with pre-existing structural heart disease.12

Zall et al advise against adenosine use in patients with impaired renal function, secondary to its profound decrease in renal blood flow and glomerular filtration rate. This effect is temporary, not associated with renin release and rapidly reverses with discontinuation of adenosine.9 Neither rebound hypertension nor tachyphylaxis has been shown to occur after adenosine, likely because it does not activate renin–angiotensin system.15 27

Many patients presenting with aneurysmal subarachnoid haemorrhage are medicated with nimodipine for vasospasm prophylaxis. However, as noted above, nimodipine can inhibit adenosine breakdown and uptake, and thus, care must be exercised when using adenosine during clipping of a ruptured aneurysm that is being treated with nimodipine.24 In fact, Groff et al recorded electroencephalography (EEG) and somatosensory evoked potentials (SSEPs) during adenosine use in one patient and found decreased EEG activity secondary to ischaemia but no change in SSEPs. Thus, they recommend avoiding adenosine use in patients with subarachnoid haemorrhage who may be more sensitive to ischaemia from vasospasm.8 Other authors believe adenosine can be used safely in preoperatively or intraoperatively ruptured aneurysms in patients with no pre-existing cardiac abnormalities.7 26

Because of adenosine’s actions on bronchial smooth muscle, it may cause bronchoconstriction and thus, may be contraindicated in patients with asthma or COPD.15 23

As noted above, exogenous adenosine is mostly eliminated by cellular uptake into vascular endothelium...
and erythrocytes. But it can also be metabolised to uric acid and increase uric acid levels by 15%. Although this increase has been non-pathological to date, adenosine should be used cautiously in those with gout or purine metabolism defects.\textsuperscript{14,23}

Cerqueira \textit{et al} identified risk factors for any adenosine side effect, including flushing, dyspnoea, chest pain, headache to ECG changes such as AV block, ST changes and more. Female gender OR was 1.78, body weight above median OR 1.47 and patients younger than median age OR 1.52. The authors note that these ORs are low and do not allow for clinical prediction of an adverse event in a particular patient.\textsuperscript{26}

**COMPlications**

While adenosine use has been shown to be relatively safe with no complications in multiple studies, other studies have had rare complications.\textsuperscript{11,18,26}

Transient cardiac arrhythmias are occasionally seen, more commonly in those with a preoperative history of MI.\textsuperscript{14} These are typically clinically insignificant with spontaneous recovery and with no long-term sequelae.\textsuperscript{4,16,17}

Rarely, elevated troponins can occur. Bendok \textit{et al} had two such patients but neither developed acute changes on ECG or echocardiogram.\textsuperscript{17} Bebawy \textit{et al} also had two patients who developed transient, asymptomatic troponin increases postoperatively but had no symptoms and no cardiac dysfunction on transthoracic echocardiogram.\textsuperscript{1}

Based on these results, they recommend placement of external defibrillator pads on all patients who may receive adenosine as well as postoperative troponin monitoring.\textsuperscript{48}

Khan \textit{et al} retrospectively reviewed 64 cases of adenosine use during aneurysmal surgery compared with 262 cases where adenosine was not used to determine perioperative cardiac complications and 30-day mortality. The authors dosed adenosine in increments of 6–12 mg boluses to achieve 30 s of cardiac arrest. This dose was repeated at the request of the surgeon. The primary outcome was a composite of mortality within 30 days or a perioperative adverse cardiac event such as an MI or arrhythmia. After adjusting for incidence of coronary artery disease, the odds of reaching the primary outcome was the same between both groups, and there were no differences in length of hospital or intensive care unit stay.\textsuperscript{3}

Adenosine use in cases other than cerebral aneurysm surgery has also shown limited and transient adverse consequences. Kahn \textit{et al} report a case series on endovascular aortic aneurysm repair using an initial dose of 24 mg that was escalated until 10 s of asystole occurred. They observed a 9% incidence of mild cardiac complication: 2% incidence of self-limited ST depression, 2% atrial fibrillation requiring cardioversion, 1% transient left bundle branch block lasting <10 s and 4% temporary heart block requiring pacing for <30 s. They had no cases of bronchospasm or worsening obstructive pulmonary disease.\textsuperscript{28}

In 2014, Deb \textit{et al} reported a case in which intraoperative aneurysmal rupture led to 1.5 L of blood loss; to reduce blood loss, two sequential adenosine boluses were administered, which lead to cardiac arrest and required electrical cardioversion.\textsuperscript{25} She awoke with lower cranial nerve palsy, resulting in tracheostomy and prolonged hospitalisation. This patient had a history of interstitial lung disease, suggesting that patients with these comorbidities may be at higher risk for an adverse cardiac event resulting from adenosine use after intraoperative aneurysmal rupture.\textsuperscript{25}

In another case of intraoperative rupture with 500 mL of blood loss and hypotension, rapid redosing of adenosine, before full recovery of cardiac function, prolonged the hypotensive period and required chest compressions.\textsuperscript{2} Thus, prior to repeat dosing, it is important to have proper return of cardiac function.\textsuperscript{2,3,7,15} Otherwise, a carry-over effect or tachyphylaxis may be seen, although it has not been reported in the literature as of yet during cerebral aneurysm surgery.\textsuperscript{17}

Given the possibility of transient or prolonged duration of hypotension, concern for neurological ischemic complications exists. Bebawy \textit{et al} investigated the neurological safety profile of adenosine, comparing the incidence of neurological complications with and without adenosine use.\textsuperscript{29} Although there is no mention of dosage amount or regimen, their results show that adenosine use was not associated with an increased neurological complication rate, defined as modified Rankin score >2 at 48 hours postoperatively or at the time of discharge.\textsuperscript{29}

**CONCLUSIONS AND FUTURE DIRECTIONS**

Adenosine has been used successfully for ruptured and unruptured aneurysms in anterior and posterior circulations with a rare incidence of clinically significant side effects. Its rapid onset and offset and predictable action make it a valuable tool in cerebrovascular surgery. Most evidence to date has been in the form of case series or retrospective reviews (see online supplementary table 1), signifying the need for a prospective, randomised trial of adenosine usage.

**Contributors** VRD, ALR and GWB contributed significantly to this work, including the concept and design of the project and the drafting, revising and final approval. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**Disclaimer** The views expressed within this article are those of the authors alone and not an official position of the institution Houston Methodist Hospital.

**Competing interests** None declared.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) licence, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
REFERENCES